SLC29A1 and Hodgkins lymphoma: Immunochemistry assays for hENT1 was correlated with clinical outcome in CALGB 59804 multicenter trial in Hodgkin lymphoma treated with the cytarabine congener gemcitabine; in this study, the opposite of the logical expected result was found since patients with high hENT expression had a lower likelihood of response and failure-free survival [171,172].